A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
Withdrawn before enrolling · Phase 1
Conditions studied: Metastatic Melanoma
In brief
The main purpose of this study is to investigate the utility of the new investigational imaging agent ⁸⁹Zr Df-IAB22M2C (CD8 PET/CT tracer) to monitor CD8 T-cell expansion and trafficking within tumors and associated tissues in patients with metastatic melanoma undergoing treatment with bempegaldesleukin and nivolumab as a single agent and in combination.
Key facts
- Study ID
- NCT04955262
- Run by
- Nektar Therapeutics
- People needed
- 0
- Starts
- 2019-08-01
- Expected to finish
- 2022-01-01
- Last updated by the study team
- 2021-07-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Investigational Site - Duarte — Duarte, California, United States
- Investigational Site - Portland — Portland, Oregon, United States
- Investigational Site - Philadelphia — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.